The Global Radiodermatitis Market Continues To Grow Owing To the Rise of Cancer Cases in the World Along With the Launch of Various Advanced Radiotherapy Processes


Radiodermatitis is an acute burn injury that varies significantly in severity depending on both patient characteristics and treatment. Most acute radiodermatitis recurs within several months after its initial onset but some common treatments persist and may even lead to complications. This type of burns can be caused by overexposure to sunlight or heat, chemicals, and medical interventions such as chemotherapy, but the most common reasons for the disease are faulty burn pit management and inappropriate antinuclear antibodies (panleukopenia). Burns are categorized into two: non-traumatic and traumatic. Non-traumatic burns occur spontaneously and do not require medical treatment; the main threat posed by non-traumatic burn injuries is the risk of secondary bacterial infection and subsequent pneumonia; traumatic burns occur when the patient is subject to a sudden, destructive flame, usually resulting in death, disability, and lifelong visual impairment.

Patients with non-traumatic acute radiodermatitis experience redness, itching, and irritation before pain and warmth develop. Radiodermatitis typically develops in four stages: redness, scaling, peeling, and cracking. In cases of non-traumatic radiodermatitis bronchitis, the condition may clear up within a few days if prompt treatment is administered. On the other hand, patients diagnosed with traumatic burn conditions often require prolonged hospitalization due to the very serious complications that may arise if no medical interventions are introduced after the damage is done.

The increasing prevalence of cancer is the main factor that is propelling the growth of the global radiodermatitis market. For instance, according to the International Agency for Research on Cancer (IARC), 1 in every 5 individuals in the world gets cancer. The new estimates suggest that over 50 million individuals in the world are living within 5 years of a previous cancer diagnosis. Moreover, the research and development of new therapies for radiodermatitis treatment are also augmenting the growth of the global radiodermatitis market.

Patients with acute bronchitis or pneumonia may require hospitalization for a period ranging from three to six weeks. The most common complications associated with this condition include hospital admissions for cardiopulmonary resuscitation, lung function tests, and pneumonia due to the accumulation of toxins in the lungs. One of the most successful ways to treat acute radiodermatitis involves the use of pulsed dye laser therapy. This treatment option targets the underlying cause of the problem rather than providing symptomatic relief. However, the introduction of better radiation therapy processes is the main factor that is limiting the growth of the global radiodermatitis market.

Owing to the increase of cancer in the region, North America is witnessing high growth in the global radiodermatitis market. For instance, according to the American Cancer Society, in 2019, around 1,762,450 new cancer cases were diagnosed and 606,880 cancer-related deaths were registered in the US. Moreover, the advancements in cancer therapies in the region are also boosting the growth of the market. Owing to such factors, there have been significant developments in the global radiodermatitis market. For instance, in October 2019, Acelity, Inc. and its KCI subsidiaries were acquired by 3M.

Comments

Popular posts from this blog

U.S. Meibomian Gland Dysfunction Market is growing rapidly with ThermaMEDx introducing a self-healing, disposable, pre-moistened, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction

Boston Sci Launched A New Device For Erectile Dysfunction Devices Market

Bakeable Trays Market Estimated To Develop At Cagr at 4.8% During Estimate Duration 2019-2027